Company webinar

Invion (ASX:IVX)

Watch our webinar with Invion, featuring Chair and CEO Thian Chew. A presentation followed by live Q&A with the audience.

Date
September 23, 2024
Time
Where
Online
Entry
Free
Thian Chew
Thian Chew
Chair and CEO, Invion (ASX:IVX)

About the company

Invion (ASX: IVX) is a clinical stage company developing the next-generation Photodynamic Therapy (PDT), called Photosoft, for the treatment of a range of cancers and infectious diseases. Invion is undertaking its Ph I/II human trials on skin cancer this year and more trials to treat other cancers are scheduled over the next 12-24 months.

Pre-clinical results undertaken by Invion's research partners, the Peter MacCallum Cancer Centre and Hudson Institute of Medical Research, showed that the technology completely regressed a range of cancers, such as triple negative breast and ovarian cancers, is non scarring and stimulated the body's immune system to continue fighting the cancer.

Invion's lead drug candidate is INV043, a novel, patent protected photosensitiser, has the potential to work as a therapy and a diagnostic tool. Under a certain wavelength of red light, it selectively kills cancer cells and promotes an immune response with the potential to attack other related cancers. Under violet light, it causes tumours to fluoresce.

Key topics

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →